Diagnosis and management of cancer therapy-related myocarditis in a young female: A case report and review of literature
- PMID: 38858610
- PMCID: PMC11163803
- DOI: 10.1186/s12872-024-03960-6
Diagnosis and management of cancer therapy-related myocarditis in a young female: A case report and review of literature
Abstract
Background: The treatment of choice for Extra-osseous Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET), a rare neoplasm, is the VAC/IE regimen. This regimen includes Doxorubicin, Vincristine, Cyclophosphamide, Ifosfamide, and Etoposide, all of which have cardiotoxic effects. Myocarditis, a potentially threatening side effect following cancer therapy, can be accurately managed and diagnosed.
Case presentation: In the current study, we report the case of a 19-year-old female with a mass on the abdominal wall, diagnosed with ES/PNET. She was treated with the VAC/IE regimen. A month after the last session of chemotherapy, she experienced dyspnea. Upon evaluation, a high level of troponin and a low left ventricular ejection fraction (LVEF) were detected via transthoracic echocardiography. She was treated with anti-heart failure drugs, but the response was unsatisfactory. The possibility of Cancer therapy-related myocarditis was suspected, and cardiac magnetic resonance imaging (CMR) confirmed acute myocarditis. This patient exhibited a significant response to intravenous immunoglobulin (IVIG), with her LVEF improving from 30-35% to 50% within three months.
Conclusion: In this case, based on negative tests and the absence of viral signs and symptoms, Cancer therapy-related myocarditis is highly suspected as the cause of myocarditis. This case underscores the importance of accurately utilizing CMR as a non-invasive method for diagnosing myocarditis. It effectively highlights the identification of reversible myocarditis with appropriate treatment and the notable response to IVIG, suggesting its potential as a favorable treatment for myocarditis in younger patients.
Keywords: Anthracyclines; Cardiotoxicity; Chemotherapy; Ewing; Myocarditis; Sarcoma.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.J Clin Oncol. 2001 Feb 1;19(3):870-80. doi: 10.1200/JCO.2001.19.3.870. J Clin Oncol. 2001. PMID: 11157041 Review.
-
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.N Engl J Med. 2003 Feb 20;348(8):694-701. doi: 10.1056/NEJMoa020890. N Engl J Med. 2003. PMID: 12594313 Clinical Trial.
-
Esophageal extraskeletal neoplasm Ewing's sarcoma: Case report.Int J Surg Case Rep. 2022 Aug;97:107399. doi: 10.1016/j.ijscr.2022.107399. Epub 2022 Jul 9. Int J Surg Case Rep. 2022. PMID: 35926382 Free PMC article.
-
Intravenous immunoglobulin for presumed viral myocarditis in children and adults.Cochrane Database Syst Rev. 2020 Aug 19;8(8):CD004370. doi: 10.1002/14651858.CD004370.pub4. Cochrane Database Syst Rev. 2020. PMID: 32835416 Free PMC article.
-
[Primitive cutaneous Ewing's sarcoma: a diagnostic and therapeutic dilemma].Ann Dermatol Venereol. 2011 May;138(5):395-8. doi: 10.1016/j.annder.2010.11.010. Epub 2010 Dec 24. Ann Dermatol Venereol. 2011. PMID: 21570564 French.
Cited by
-
Review of the Interactions Between Anesthetic Agents and Chemotherapeutic Agents in Cancer Cell Lines Studied In Vitro.Med Sci Monit. 2025 Feb 27;31:e947071. doi: 10.12659/MSM.947071. Med Sci Monit. 2025. PMID: 40012181 Free PMC article. Review.
-
Potential value and cardiovascular risks of programmed cell death in cancer treatment.Front Pharmacol. 2025 Jul 3;16:1615974. doi: 10.3389/fphar.2025.1615974. eCollection 2025. Front Pharmacol. 2025. PMID: 40678726 Free PMC article. Review.
-
NADPH Oxidases in Cancer Therapy-Induced Cardiotoxicity: Mechanisms and Therapeutic Approaches.Cardiovasc Toxicol. 2025 Apr;25(4):631-649. doi: 10.1007/s12012-025-09976-4. Epub 2025 Feb 18. Cardiovasc Toxicol. 2025. PMID: 39966326 Review.
References
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources